Enhanced Commendable Sensitivity and Specificity for MSI in Colorectal Cancer by a New PCR‐HRM Based 8‐Loci MSI Assay

Abstract

BackgroundThis study evaluated the performance of the PCR‐HRM assay by comparing it with immunohistochemistry (IHC) for mismatch repair (MMR) proteins and the PCR capillary electrophoresis (PCR‐CE) methods.ResultsA total of 224 patients with colorectal cancer participated in the study, with nearly half having mismatch repair deficiency (dMMR) tissues and the remainder possessing pMMR tissues. There was a 97.77% concordance between the PCR‐HRM assay and IHC, and a 97.56% concordance between PCR‐HRM and the PCR‐CE assay. In comparison with IHC for dMMR proteins, the PCR‐HRM demonstrated a sensitivity of 96.36% and a specificity of 99.12%. When juxtaposed with the PCR‐CE assay, its sensitivity was 98.96% and specificity stood at 96.33%. The mutations observed in the microsatellite loci were uniformly distributed across all eight loci. Discrepant outcomes were more frequent in instances of MLH1 and PMS2 deficiency. Furthermore, the germline mutation status of MLH1, MSH2, PMS2, and MSH6 in 62 patients was ascertained using next‐generation sequencing. All patients displaying MMR gene pathogenic mutations (N = 14) were identified as MSI‐H by PCR‐HRM, whereas those with MSS tissues (N = 43) did not exhibit MMR gene pathogenic mutations. Thus, the PCR‐HRM method proficiently pinpoints tumors with verified germline MMR mutations, indicative of Lynch syndrome.ConclusionConclusively, the PCR‐HRM assay emerges as a swift and congruent diagnostic tool for microsatellite instability, boasting commendable sensitivity and specificity in colorectal cancer.